Partners

ALGAVILLAGE, proyecto conjunto de la compañía británica Firglas y la biotecnológica almeriense Biorizon Biotech, avanza...

Oryzon invests $8.1 million in R&D in the first half 2022

To explore Oryzon’s HDAC6 inhibitors on Charcot-Marie-Tooth disease CMTRF to provide funding for in vivo efficacy tests...

GENESIS Biomed will be the managing entity of the vehicle

This new launch follows a trend of expansion of the Spanish brand after its success in Europe and the Americas, with a...

PVPHARM, a leading company in specialized pharmacovigilance and clinical safety services, has a group of experts that...

The company plans to continue pushing forward the development of in silico enzyme discovery and design projects in the...

Oryzon and NCI will collaborate to assess the safety and efficacy of iadademstat in oncology patients with different...

Almirall recently announced topline results from one-year analyses of the efficacy and safety of lebrikizumab, an...

The event made public the winning projects that put the patient at the centre of the healthcare system unveiled